Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
Q1 2026 earnings • released • EPS beat +70,18% • Revenue beat +64,58%
See results
MRNA:NASDAQ
Moderna Inc
45,37 US$
-1,24%
(-0,57) 1D
45,17 US$
-0,44% (-0,20)
After hours
Closed: 1 may, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRNA...
Açın
46,64 US$
High
48,40 US$
Low
43,68 US$
Mkt. cap
17,99 mlrd
Avg. vol.
6,37 mln
Volume
10,23 mln
52-wk high
59,55 US$
52-wk low
22,28 US$
EPS
-7,25 US$
Beta
1,33
Shares outstanding
396,59 mln
No. of employees
5K
News stories
From sources across the web
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. Wikipedia
About Moderna Inc
CEOStéphane Bancel
Employees4,7K
Foundedsen 2010
Headquarters-
Sector-
Websitemodernatx.com
Last report
1 may 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-1,18/ (-3,96 est.)USD
+70,18%beat
Revenue / Estimate
389,00 mln/ (236,36 mln est.)USD
+64,58%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
108,00 mln
142,00 mln
1,02 mlrd
678,00 mln
Cost of goods sold
946,00 mln
819,00 mln
1,01 mlrd
1,23 mlrd
Cost of revenue
946,00 mln
819,00 mln
1,01 mlrd
1,23 mlrd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
212,00 mln
230,00 mln
268,00 mln
308,00 mln
Operating expense
212,00 mln
230,00 mln
268,00 mln
308,00 mln
Total operating expenses
1,16 mlrd
1,05 mlrd
1,28 mlrd
1,54 mlrd
Operating income
-1,05 mlrd
-907,00 mln
-260,00 mln
-857,00 mln
Other non operating income
4,00 mln
9,00 mln
-4,00 mln
-2,00 mln
EBT including unusual items
-964,00 mln
-818,00 mln
-187,00 mln
-799,00 mln
EBT excluding unusual items
-957,00 mln
-818,00 mln
-191,00 mln
-797,00 mln
Income tax expense
7,00 mln
7,00 mln
13,00 mln
27,00 mln
Effective tax rate
-0,73%
-0,86%
-6,95%
-3,38%
Other operating expenses
-
-
-
-
Net income
-971,00 mln
-825,00 mln
-200,00 mln
-826,00 mln
Net profit margin
-899,07%
-580,99%
-19,68%
-121,83%
Earnings per share
-2,52
-2,13
-0,51
-2,11
Interest and investment income
90,00 mln
81,00 mln
73,00 mln
70,00 mln
Interest expense
-1,00 mln
-1,00 mln
-
-8,00 mln
Net interest expenses
89,00 mln
80,00 mln
73,00 mln
62,00 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,01 mlrd
-850,00 mln
-208,00 mln
-790,00 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer